Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LANA D MELENDRES GROVES

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1548309537
CMS profile
749288
Location
ALBUQUERQUE, NM

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$196,218.68

164 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Merck Sharp & Dohme LLC $71,370.75 71
United Therapeutics Corporation $70,228.41 47
Actelion Pharmaceuticals US, Inc. $47,506.96 41
Bayer Healthcare Pharmaceuticals Inc. $7,112.56 5

Page 4 of 4; records 151–164 of 164 matching records. This page contains 14 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LANA D MELENDRES GROVES

NPI 1548309537 · CMS profile ID 749288

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

ALBUQUERQUE, NM

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–164 of 164 matching records. This page contains 14 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1548309537?year=2025&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LANA D MELENDRES GROVES, NPI 1548309537, CMS profile ID 749288. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–164 of 164 matching records. This page contains 14 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1548309537?year=2025&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). LANA D MELENDRES GROVES, NPI 1548309537, CMS profile ID 749288. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–164 of 164 matching records. This page contains 14 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1548309537?year=2025&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
LANA D MELENDRES GROVES, NPI 1548309537, CMS profile ID 749288, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–164 of 164 matching records. This page contains 14 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1548309537?year=2025&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

164 matching records · $196,218.68 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 164 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–164 of 164.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
United Therapeutics Corporation $24.4902/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242551740 CMS
Merck Sharp & Dohme LLC $305.0002/26/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1238028410 CMS
United Therapeutics Corporation $110.8402/26/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1242525756 CMS
Bayer Healthcare Pharmaceuticals Inc. $47.2602/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225650758 CMS
Bayer Healthcare Pharmaceuticals Inc. $133.0902/21/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1225650766 CMS
Actelion Pharmaceuticals US, Inc. $147.4702/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174259439 CMS
United Therapeutics Corporation $2,840.0002/19/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1242553082 CMS
United Therapeutics Corporation $263.8202/16/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1242526894 CMS
United Therapeutics Corporation $533.9601/31/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1242526978 CMS
Bayer Healthcare Pharmaceuticals Inc. $241.9701/18/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1225650762 CMS
Actelion Pharmaceuticals US, Inc. $117.1701/14/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1174259108 CMS
Actelion Pharmaceuticals US, Inc. $166.8301/10/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1174259042 CMS
Actelion Pharmaceuticals US, Inc. $28.0001/10/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1174259197 CMS
United Therapeutics Corporation $373.5901/02/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1242526470 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $167,525.69 228
PY2020 $115,201.34 105
PY2021 $110,688.82 94
PY2022 $143,513.28 109
PY2023 $160,109.90 153
PY2024 $201,984.61 197
PY2025 $196,218.68 164

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $562,020.89 32
PY2024 Principal investigator $448,410.66 20
PY2023 Principal investigator $633,149.36 33
PY2022 Principal investigator $190,731.97 32
PY2021 Principal investigator $65,070.69 27
PY2020 Principal investigator $181,776.06 36
PY2019 Principal investigator $92,265.12 12

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

32 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $38,914.81 12/31/2025 Non-covered Recipient Entity
University of New Mexico Health Sciences Center
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Background Therapy in Participants With Pulmonary Arterial Hypertension PAH World Health Organization WHO Functional Class FC III o No dispute reported 06/30/2026 1232917625
Principal investigator 1 Merck Sharp & Dohme LLC $11,829.50 12/31/2025 Non-covered Recipient Entity
University of New Mexico Health Sciences Center - Department of Internal Medicine
A Phase 2, Multicenter, Single-blinded, Randomized Study to Evaluate the Pharmacokinetics and Safety of Sotatercept MK-7962 Administered Using Either a Weight-based or Weight-banded Approach in Participants With Pulmonary Arterial Hypertension PAH on No dispute reported 06/30/2026 1232936302
Principal investigator 1 Merck Sharp & Dohme LLC $323,216.40 12/31/2025 Non-covered Recipient Entity
University of New Mexico Health Sciences Center
An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension PAH Therapy for the Treatment of PAH No dispute reported 06/30/2026 1232938150
Principal investigator 1 Merck Sharp & Dohme LLC $7,558.17 12/31/2025 Non-covered Recipient Entity
University of New Mexico Health Sciences Center - Department of Internal Medicine
An Open-label Extension Study to Evaluate Safety and Tolerability of Sotatercept MK-7962 Administered Using a Weight-banded Approach in Participants With Pulmonary Arterial Hypertension PAH on Standard of Care No dispute reported 06/30/2026 1232938462
Principal investigator 1 Merck Sharp & Dohme LLC $2,863.92 12/31/2025 Non-covered Recipient Entity
University of New Mexico Health Sciences Center - Department of Internal Medicine
An Open-label Extension Study to Evaluate Safety and Tolerability of Sotatercept MK-7962 Administered Using a Weight-banded Approach in Participants With Pulmonary Arterial Hypertension PAH on Standard of Care No dispute reported 06/30/2026 1232938464
Principal investigator 1 United Therapeutics Corporation $2,431.80 12/17/2025 Non-covered Recipient Entity
UNIVERSITY OF NEW MEXICO HSC
A STUDY EVALUATING THE LONG-TERM EFFICACY AND SAFETY OF RALINEPAG IN SUBJECTS WITH PAH VIA AN OPEN-LABEL EXTENSION No dispute reported 06/30/2026 1242391165
Principal investigator 1 United Therapeutics Corporation $429.30 12/15/2025 Non-covered Recipient Entity
UNIVERSITY OF NEW MEXICO HSC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDED TO PAH STANDARD OF CARE OR PAH-SPECIFIC BACKGROUND ORAL THERAPY IN SUBJECTS WITH WHO GROUP I PULMONARY HYPERTENSION No dispute reported 06/30/2026 1242391133
Principal investigator 1 United Therapeutics Corporation $2,560.00 12/05/2025 Non-covered Recipient Entity
UNIVERSITY OF NEW MEXICO HSC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDED TO PAH STANDARD OF CARE OR PAH-SPECIFIC BACKGROUND ORAL THERAPY IN SUBJECTS WITH WHO GROUP I PULMONARY HYPERTENSION No dispute reported 06/30/2026 1242391143
Principal investigator 1 Merck Sharp & Dohme LLC $77,401.00 12/03/2025 Non-covered Recipient Entity
University of New Mexico Health Sciences Center - Department of Internal Medicine
A Phase 2, Multicenter, Single-blinded, Randomized Study to Evaluate the Pharmacokinetics and Safety of Sotatercept MK-7962 Administered Using Either a Weight-based or Weight-banded Approach in Participants With Pulmonary Arterial Hypertension PAH on No dispute reported 06/30/2026 1232938782
Principal investigator 1 United Therapeutics Corporation $1,600.00 12/03/2025 Non-covered Recipient Entity
UNIVERSITY OF NEW MEXICO HSC
A STUDY EVALUATING THE LONG-TERM EFFICACY AND SAFETY OF RALINEPAG IN SUBJECTS WITH PAH VIA AN OPEN-LABEL EXTENSION No dispute reported 06/30/2026 1242391163
Principal investigator 1 United Therapeutics Corporation $2,723.40 11/20/2025 Non-covered Recipient Entity
UNIVERSITY OF NEW MEXICO HSC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDED TO PAH STANDARD OF CARE OR PAH-SPECIFIC BACKGROUND ORAL THERAPY IN SUBJECTS WITH WHO GROUP I PULMONARY HYPERTENSION No dispute reported 06/30/2026 1242391145
Principal investigator 1 United Therapeutics Corporation $3,869.44 11/19/2025 Non-covered Recipient Entity
UNIVERSITY OF NEW MEXICO HSC
A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) No dispute reported 06/30/2026 1242391241
Principal investigator 1 United Therapeutics Corporation $6,019.84 11/07/2025 Non-covered Recipient Entity
UNIVERSITY OF NEW MEXICO HSC
A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) No dispute reported 06/30/2026 1242391243
Principal investigator 1 Merck Sharp & Dohme LLC $18,561.20 11/05/2025 Non-covered Recipient Entity
University of New Mexico Health Sciences Center - Department of Internal Medicine
An Open-label Extension Study to Evaluate Safety and Tolerability of Sotatercept MK-7962 Administered Using a Weight-banded Approach in Participants With Pulmonary Arterial Hypertension PAH on Standard of Care No dispute reported 06/30/2026 1232938460
Principal investigator 1 United Therapeutics Corporation $5,204.70 10/16/2025 Non-covered Recipient Entity
UNIVERSITY OF NEW MEXICO HSC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDED TO PAH STANDARD OF CARE OR PAH-SPECIFIC BACKGROUND ORAL THERAPY IN SUBJECTS WITH WHO GROUP I PULMONARY HYPERTENSION No dispute reported 06/30/2026 1242391149
Principal investigator 1 United Therapeutics Corporation $576.00 09/22/2025 Non-covered Recipient Entity
UNIVERSITY OF NEW MEXICO HSC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDED TO PAH STANDARD OF CARE OR PAH-SPECIFIC BACKGROUND ORAL THERAPY IN SUBJECTS WITH WHO GROUP I PULMONARY HYPERTENSION No dispute reported 06/30/2026 1242391135
Principal investigator 1 United Therapeutics Corporation $960.00 09/03/2025 Non-covered Recipient Entity
UNIVERSITY OF NEW MEXICO HSC
A STUDY EVALUATING THE LONG-TERM EFFICACY AND SAFETY OF RALINEPAG IN SUBJECTS WITH PAH VIA AN OPEN-LABEL EXTENSION No dispute reported 06/30/2026 1242391157
Principal investigator 1 Merck Sharp & Dohme LLC $3,259.51 08/31/2025 Non-covered Recipient Entity
University of New Mexico Health Sciences Center - Department of Internal Medicine
A Phase 2, Multicenter, Single-blinded, Randomized Study to Evaluate the Pharmacokinetics and Safety of Sotatercept MK-7962 Administered Using Either a Weight-based or Weight-banded Approach in Participants With Pulmonary Arterial Hypertension PAH on No dispute reported 06/30/2026 1232936304
Principal investigator 1 United Therapeutics Corporation $1,665.00 08/13/2025 Non-covered Recipient Entity
UNIVERSITY OF NEW MEXICO HSC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDED TO PAH STANDARD OF CARE OR PAH-SPECIFIC BACKGROUND ORAL THERAPY IN SUBJECTS WITH WHO GROUP I PULMONARY HYPERTENSION No dispute reported 06/30/2026 1242391139
Principal investigator 1 United Therapeutics Corporation $5,342.40 07/18/2025 Non-covered Recipient Entity
UNIVERSITY OF NEW MEXICO HSC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDED TO PAH STANDARD OF CARE OR PAH-SPECIFIC BACKGROUND ORAL THERAPY IN SUBJECTS WITH WHO GROUP I PULMONARY HYPERTENSION No dispute reported 06/30/2026 1242391151
Principal investigator 1 United Therapeutics Corporation $960.00 07/16/2025 Non-covered Recipient Entity
UNIVERSITY OF NEW MEXICO HSC
A STUDY EVALUATING THE LONG-TERM EFFICACY AND SAFETY OF RALINEPAG IN SUBJECTS WITH PAH VIA AN OPEN-LABEL EXTENSION No dispute reported 06/30/2026 1242391159
Principal investigator 1 United Therapeutics Corporation $7,948.80 07/16/2025 Non-covered Recipient Entity
UNIVERSITY OF NEW MEXICO HSC
A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) No dispute reported 06/30/2026 1242391245
Principal investigator 1 United Therapeutics Corporation $1,600.00 07/14/2025 Non-covered Recipient Entity
UNIVERSITY OF NEW MEXICO HSC
A STUDY EVALUATING THE LONG-TERM EFFICACY AND SAFETY OF RALINEPAG IN SUBJECTS WITH PAH VIA AN OPEN-LABEL EXTENSION No dispute reported 06/30/2026 1242391161
Principal investigator 1 United Therapeutics Corporation $1,960.20 06/18/2025 Non-covered Recipient Entity
UNIVERSITY OF NEW MEXICO HSC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDED TO PAH STANDARD OF CARE OR PAH-SPECIFIC BACKGROUND ORAL THERAPY IN SUBJECTS WITH WHO GROUP I PULMONARY HYPERTENSION No dispute reported 06/30/2026 1242391141
Principal investigator 1 United Therapeutics Corporation $960.00 06/13/2025 Non-covered Recipient Entity
UNIVERSITY OF NEW MEXICO HSC
A STUDY EVALUATING THE LONG-TERM EFFICACY AND SAFETY OF RALINEPAG IN SUBJECTS WITH PAH VIA AN OPEN-LABEL EXTENSION No dispute reported 06/30/2026 1242391155
Principal investigator 1 United Therapeutics Corporation $7,713.00 05/14/2025 Non-covered Recipient Entity
UNIVERSITY OF NEW MEXICO HSC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDED TO PAH STANDARD OF CARE OR PAH-SPECIFIC BACKGROUND ORAL THERAPY IN SUBJECTS WITH WHO GROUP I PULMONARY HYPERTENSION No dispute reported 06/30/2026 1242391153
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,530.00 04/28/2025 Non-covered Recipient Entity
University Of New Mexico Health Sciences Center
BAY 632521, RiOciguAt UseRs Registry The ROAR registry No dispute reported 06/30/2026 1225419721
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,200.00 04/28/2025 Non-covered Recipient Entity
University Of New Mexico Health Sciences Center
BAY 632521, RiOciguAt UseRs Registry The ROAR registry No dispute reported 06/30/2026 1225419789
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $960.00 04/28/2025 Non-covered Recipient Entity
University Of New Mexico Health Sciences Center
BAY 632521, RiOciguAt UseRs Registry The ROAR registry No dispute reported 06/30/2026 1225419839
Principal investigator 1 United Therapeutics Corporation $3,861.90 04/14/2025 Non-covered Recipient Entity
UNIVERSITY OF NEW MEXICO HSC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDED TO PAH STANDARD OF CARE OR PAH-SPECIFIC BACKGROUND ORAL THERAPY IN SUBJECTS WITH WHO GROUP I PULMONARY HYPERTENSION No dispute reported 06/30/2026 1242391147
Principal investigator 1 United Therapeutics Corporation $11,482.00 03/14/2025 Non-covered Recipient Entity
UNIVERSITY OF NEW MEXICO HSC
A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) No dispute reported 06/30/2026 1242391247
Principal investigator 1 United Therapeutics Corporation $858.60 01/22/2025 Non-covered Recipient Entity
UNIVERSITY OF NEW MEXICO HSC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDED TO PAH STANDARD OF CARE OR PAH-SPECIFIC BACKGROUND ORAL THERAPY IN SUBJECTS WITH WHO GROUP I PULMONARY HYPERTENSION No dispute reported 06/30/2026 1242391137